Shijiazhuang Yiling Pharmaceutical Co., Ltd.
002603.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$25.95B
Close$
$9.94
33.8% downside
Current Fair Value
33.8% downsideOvervalued by 33.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $25.95 Billion |
|---|---|
| Enterprise Value | $25.48 Billion |
| Dividend Yield | $0.80 (5.15%) |
| Earnings per Share | $0.77 |
| Beta | 0.47 |
| Outstanding Shares | 1,670,705,376 |
Return
| Return on Equity | 12.60% |
|---|---|
| Return on Assets | 9.83% |
| Return on Invested Capital | 14.63% |
Valuation & Multiples
| P/E Ratio | 18.94 |
|---|---|
| PEG | 1105.69 |
| Price to Sales | 3.75 |
| Price to Book Ratio | 2.5 |
| Enterprise Value to Revenue | 3.24 |
| Enterprise Value to EBIT | 15.31 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Shijiazhuang Yiling Pharmaceutical Co., Ltd.
11,343 employees
CEO: Xiang Jun Wu Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for cardiovascular and cerebrovascular, respiratory, endocrine, neurologic...